Home
Solutions
Integrated Solutions
Human Challenge Model Advantage

Human Challenge Model Advantage

With more than 25 years experience in delivering Human Challenge Trials, hVIVO is the world leader. With a 50 bed quarantine unit and integrated laboratory facility, industry-leading scientific and regulatory experts hVIVO provides unparalleled delivery

Schedule a Call

Human Challenge Model Advantage

Human challenge models provide a scientifically rigorous and highly controlled method to generate early efficacy signals, enabling sponsors to reach proof‑of‑concept (PoC) up to 3.5× faster than conventional outpatient trials. By using validated challenge strains, controlled exposure, and rapid readouts, human challenge studies de‑risk clinical development and accelerate decision‑making for vaccines, antivirals, monoclonals, and immunomodulators.

Proven to accelerate PoC up to 3.5× faster then field trials
Controlled viral/bacterial exposure enabling precise efficacy measurement
Integrated clinical and laboratory environment for rapid decision‑making
End‑to‑end challenge model design, delivery, and interpretation
Faster execution enabled by agile governance & rapid project start‑up

Integrated Human Challenge Solution

hVIVO Capability

Human challenge trial design & delivery

Comparator strategy

In vitro/in vivo efficacy modelling

Rapid data readouts

Onsite molecular, virology, immunology & bacterial labs

Full quarantine clinical units

Challenge model development

Find out more

Fully Integrated Solution Includes

Challenge trial design & delivery

Comparator strategy

Efficacy in vitro/in vivo

Rapid data readouts

Model development

Quarantine unit – clinical conduct

Integrated specialty laboratories molecular, virology, immunology, bacterial

Why Consider hVIVO

Rapid variant analysis aligned with FDA NGS requirements

Agile challenge model development (<12 months)

Extensive track record

Top line data within one year of start up activity

FAQs

How do challenge studies accelerate PoC?

Controlled exposure enables early human efficacy signals without large outpatient trials.

What products can be evaluated?

Vaccines, antivirals, monoclonals, immunomodulators.

Do you have onsite labs?

Yes – fully integrated molecular, virology, immunology, and bacterial labs.

Can you develop new challenge models?

Yes – we design, refine, and validate bespoke challenge models.

Human Challenge Model Advantage

Human Challenge Model Advantage

hVIVO World Leaders in Human Challenge

Speak to Our Human challenge Experts

Integrated Human Challenge Solution

Why Consider hVIVO

News & Resources

From RSV to hMPV: Building the Next Generation of Respiratory Challenge Models

Controlled Human Infection Model's (CHIM) in your backpack: how Human Challenge Trials support regulatory approval of travel vaccines

Unravelling the hMPV Surge: From Media Attention to Vaccine Development

Why are Biotech’s & Pharma Using Human Challenge Studies for Drug Development?

Tripledemic Takedown: How Human Challenge Trials are Ideal to Expedite Multivalent Vaccine Development

Empowering Next‑Gen Infectious Disease & Vaccine Development

Human Challenge Studies: Their Conduct and Safety Aspects

Human Challenge Trials as a tool in raising funding

UK Life Sciences Sector Plan 2025: What it Means for the Future of Clinical Research

The UK Regulatory Competitiveness in an ever changing world

FAQs

Contact Us